Immunome (NASDAQ:IMNM) Stock Price Up 11.7% – Time to Buy?

Immunome, Inc. (NASDAQ:IMNM)’s stock price shot up 11.7% during trading on Monday . The stock traded as high as $11.25 and last traded at $12.14. 235,455 shares traded hands during trading, a decline of 76% from the average session volume of 979,078 shares. The stock had previously closed at $10.87.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on IMNM shares. Stephens assumed coverage on Immunome in a research report on Friday, November 8th. They issued an “overweight” rating and a $30.00 target price on the stock. Piper Sandler cut their price objective on Immunome from $23.00 to $21.00 and set an “overweight” rating on the stock in a report on Thursday, November 14th. Finally, Wedbush restated an “outperform” rating and issued a $33.00 price objective on shares of Immunome in a research note on Monday, January 13th. Five analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of “Buy” and an average price target of $28.60.

Immunome Trading Down 8.5 %

The company’s fifty day moving average is $11.09 and its 200-day moving average is $12.52.

Insider Buying and Selling at Immunome

In other news, CEO Clay B. Siegall acquired 150,000 shares of the firm’s stock in a transaction on Friday, January 31st. The stock was acquired at an average price of $7.75 per share, for a total transaction of $1,162,500.00. Following the completion of the transaction, the chief executive officer now owns 669,636 shares in the company, valued at approximately $5,189,679. The trade was a 28.87 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Robert Lechleider bought 15,805 shares of the company’s stock in a transaction dated Thursday, November 21st. The shares were acquired at an average price of $9.48 per share, for a total transaction of $149,831.40. Following the completion of the transaction, the insider now directly owns 15,805 shares in the company, valued at approximately $149,831.40. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last quarter, insiders purchased 252,862 shares of company stock worth $2,140,545. Insiders own 8.60% of the company’s stock.

Institutional Trading of Immunome

Several institutional investors have recently bought and sold shares of the business. AQR Capital Management LLC lifted its position in shares of Immunome by 34.6% during the 2nd quarter. AQR Capital Management LLC now owns 16,064 shares of the company’s stock valued at $194,000 after buying an additional 4,129 shares in the last quarter. Victory Capital Management Inc. lifted its holdings in Immunome by 48.1% during the third quarter. Victory Capital Management Inc. now owns 730,785 shares of the company’s stock valued at $10,684,000 after purchasing an additional 237,497 shares in the last quarter. Intech Investment Management LLC acquired a new stake in shares of Immunome in the third quarter valued at about $219,000. Primecap Management Co. CA increased its stake in shares of Immunome by 4.5% during the third quarter. Primecap Management Co. CA now owns 280,800 shares of the company’s stock worth $4,105,000 after purchasing an additional 12,000 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its position in shares of Immunome by 217.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 442,477 shares of the company’s stock worth $6,469,000 after purchasing an additional 302,916 shares during the last quarter. 44.58% of the stock is owned by institutional investors and hedge funds.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.